

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/13	C12N15/70	G01N33/53	G01N33/68	C07K16/28
	A61K39/395	C12N15/62	C12N1/21	A61P31/00	A61P7/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification numbers)

IPC 7	C12N	C07K	A61K
-------	------	------	------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 986 065 A (JIAO JIN-AN ET AL) 16 November 1999 (1999-11-16) claims 1-5 ---	1-18, 22, 37-39, 41-43
X	KIRCHHOFER D ET AL: "ANTICOAGULANT ACTIVITY OF DIFFERENT TISSUE FACTOR/FACTOR VIIA INHIBITORS IN A HUMAN EX-VIVO THROMBOSIS MODEL" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 10, SUPPL 1, 15 November 1995 (1995-11-15), page 91A XP002028014 ISSN: 0006-4971 abstract ---	1-10, 12-18, 31, 37-43



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 November 2001

Date of mailing of the international search report

04/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Le Flao, K

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 01/07501

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 51743 A (ADACHI HIDEKI ; SATO KCH (JP); YABUTA NAOHIRO (JP); CHUGAI PHARMACE) 14 October 1999 (1999-10-14) & EP 1 069 185 A (CHUGAISEIYAKU KABUSHIKI KAISHA) 17 January 2001 (2001-01-17) claims 1-93	20, 21, 23, 24
P, X	US 5 811 248 A (CHEN FRANCIS W ET AL) 22 September 1998 (1998-09-22) claims 1-28 column 105 -column 108	20, 24
A	KIRCHHOFER D ET AL: "MOLECULAR AND STRUCTURAL ADVANCES IN TISSUE FACTOR-DEPENDENT COAGULATION" TRENDS IN CARDIOVASCULAR, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 7, no. 8, November 1997 (1997-11), pages 316-324, XP000985403 ISSN: 1050-1738 the whole document	1-43
A	REFINO CANIO J ET AL: "A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo." THROMBOSIS AND HAEMOSTASIS, vol. 82, no. 3, 1999, pages 1188-1195, XP001041486 ISSN: 0340-6245 the whole document	1-43
P, X	KIRCHHOFER DANIEL ET AL: "Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies." THROMBOSIS AND HAEMOSTASIS, vol. 84, no. 6, December 2000 (2000-12), pages 1072-1081, XP001041490 ISSN: 0340-6245 the whole document	1-18, 37-43
P, X	PRESTA LEONARD ET AL: "Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic." THROMBOSIS AND HAEMOSTASIS, vol. 85, no. 3, March 2001 (2001-03), pages 379-389, XP001041497 ISSN: 0340-6245 the whole document	1-43